Abstract: A compound of general formula I wherein A is selected from the group of an unbranched or branched alky group with 1 to 12 carbon atoms, an —R1—O—R2 group, an —R1—Si(R3R4R5) group, an —R1—O—Si(R3R4R5) group, a —C(O)—O—R9—Si(R3R4R5) group, a —CH(O—R6)(O—R7) group, an —R1—CH(O—R6)(O—R7) group, or an —R1—O—C(O)—O—R8 group; SG is a protective group; R1 is a divalent hydrocarbon residue with 1 to 12 carbon atoms; R2 is a monovalent hydrocarbon residue with 1 to 12 carbon atoms; R3, R4 and R5 each independently are a monovalent hydrocarbon residue with 1 to 12 carbon atoms; R6 and R7 each independently are a monovalent hydrocarbon residue with 1 to 12 carbon atoms; R8 is a monovalent hydrocarbon residue with 1 to 12 carbon atoms; and R9 is a divalent hydrocarbon residue with 1 to 12 carbon atoms.

Abstract: The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.

Abstract: Embodiments of the present disclosure provide compositions comprising compounds useful to make radiotracers for positron emission tomography imaging, as well as methods for making and using these compositions.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: The invention relates to a compound of formula Ia or Ib wherein R1 represents —CO2R3, —COR4 or —R5, wherein R3 represents unsubstituted or substituted C1-C6 alkyl, R4 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, and R5 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, R2 represents —N+(R6)(R7)(R8)X? or a nitro group, wherein R6, R7, R8 independently of each other represent unsubstituted or substituted C1-C6 alkyl or unsubstituted or substituted —(CH2)n- with n=1 to 12 provided that at least two of the substituents R6R7R8 are C1-C6 alkyl, and X? represents a halide, sulphonate, unsubstituted or substituted acetate, sulphate, hydrogen sulphate, nitrate, perchlorate, or oxalate.

Abstract: The invention relates to a compound of formula Ia or Ib wherein R1 represents —CO2R3, —COR4 or —R5, wherein R3 represents unsubstituted or substituted C1-C6 alkyl, R4 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, and R5 represents hydrogen, unsubstituted or substituted C1-C6 alkyl, R2 represents —N+(R6)(R7)(R8)X? or a nitro group, wherein R6, R7, R8 independently of each other represent unsubstituted or substituted C1-C6 alkyl or unsubstituted or substituted —(CH2)n- with n=1 to 12 provided that at least two of the substituents R6R7R8 are C1-C6 alkyl, and X? represents a halide, sulphonate, unsubstituted or substituted acetate, sulphate, hydrogen sulphate, nitrate, perchlorate, or oxalate

Abstract: The present invention provides compounds, specifically novel tropane analogs, capable of acting as inhibitors of reuptake of monoamines. In preferred embodiments, these compositions are selective inhibitors of serotonin and/or norepinephrine reuptake. Also provided herein are pharmaceutical compositions comprising novel tropane analogs and a pharmaceutically acceptable carrier, and methods for treating conditions in which inhibition of reuptake of monoamines is desired. The inventive compositions as described herein are also useful for medical therapy and diagnosis.